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Abstract: (1) Background: colorectal cancer (CRC) is one of the deadliest causes of death by cancer
worldwide. Its first main metastatic diffusion spreads to the liver. Different mechanisms such as
the epithelial–mesenchymal transition and angiogenesis are the characteristics of this invasion. At
this stage, different options are possible and still in debate, especially regarding the use of targeted
therapeutics and biotherapies. (2) Methods: A review of the literature has been done focusing on
the clinical management of liver metastasis of colorectal cancer and the contribution of biotherapies
in this field. (3) Results: In a clinical setting, surgeons and oncologists consider liver metastasis in
CRC into two groups to launch adapted therapeutics: resectable and non-resectable. Around these
two entities, the combination of targeted therapies and biotherapies are of high interest and are
currently tested to know in which molecular and clinical conditions they have to be applied to impact
positively both on survival and quality of life of patients.
Keywords: colorectal cancer; liver metastases; immunotherapy; chemotherapy and biological agents
1. Introduction
Colorectal cancer (CRC) is the third most common cancer type, only behind breast
cancer and lung cancer in females and prostate cancer and lung cancer in males. CRC
is also a leading cause of cancer-related deaths globally. The liver is of anatomical and
physiological importance in regard to the natural course of CRC. The liver and lung are the
commonest sites for CRC metastasis to occur. The liver’s predominant blood supply arises
from the confluence of the GI tract supplying blood vessels via the hepatic portal vein; this
circulation aids the transference of the colorectal cancer cells to the hepatic parenchyma,
migrating and forming colorectal metastases in the liver. The overall prognosis and survival
of patients with CRLM are poor, and most patients initially are unable to undergo surgery.
The management of colorectal metastases of the liver varies on CRC disease burden,
patient suitability, clinical correlation and appropriateness of treatments decided by cancer
multidisciplinary team (MDT). Conventional treatment methods of CRRLM include hepatic
resection with or without chemo-radiotherapy (neoadjuvant or adjuvant) and other conser-
vative management. The development of novel and effective biotherapies in conjunction
with chemotherapies for colorectal metastases have changed the natural course of CRC by
enhancing the host’s own immunological anti-tumour responses against CRC and already
shown to have a good potential and improve the prognosis of the disease. Treatment strate-
gies utilizing and evaluating the benefit of the use of biotherapies in CRLM of the liver
remain unclear. In this review, we will examine what biotherapies are available, and the
benefits of implementing biotherapies in the context of CRLM. This review will highlight
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the current strategies and available biotherapies in use or in trials for the management and
treatment of CRC metastases of the liver.
2. Biology of the Metastatic Colorectal Cancer
Colorectal adenocarcinoma forms the largest disease type for CRCs. These adenocarci-
nomas derive from sequential changes involving mutations and key oncogenes and the loss
of suppressor genes driving changes of adenomas into adenocarcinomas [1]. These muta-
tional changes include KRAS and inactivation of tumour suppressor gene p53, which drive
the pathogenesis of adenocarcinoma from adenomas [2]. The adenoma–adenocarcinoma
sequence highlights significant avenues for targeted biological therapeutics. KRAS primar-
ily belongs to the family of GTPases. Upon activation, KRAS induces the mitogen-activated
protein kinase (MAPK) cascades and facilitates the transmission of signals from the cell
membrane to the nucleus; the RAS gene, through downstream signalling, activates RAF
proteins (including ARAF, BRAF, and RAF-1) [3,4].
The signalling pathway of the RAS–RAF–MEK–MAPK cascade regulates gene tran-
scription controlling cancer cell proliferation, survival, migration and angiogenesis, abet-
ting the progression of colorectal cancer (CRC) and promotes metastasis. Therefore, direct
inhibition of MEK binding and effector function, consequently, may uncover a promis-
ing targeted therapeutic strategy for CRCs. There are several targeted inhibitors that are
currently under evaluation in clinical trials showing initial clinical activity in a variety of
tumours, including mCRC [4–6]. Specific markers that targeted therapies are aimed against
include: Epidermal Growth Factor Receptor (EGFR), BRAF and tyrosine kinases, amongst
others.
Resistance to molecular biological targeted therapies can be detected in the early and
advanced stages of the disease, and this can occur in an estimated prevalence of up to
45% in patients with CRLM. Studies have shown that such mutations are independently
associated with worse survival and poor overall outcomes [7,8].
The use of biological therapies in combination with chemotherapy is an essential
option towards “conversional” strategies that aim to transform initially unresectable CRLM
to resectable CRLM, and thereby has evidently increased the proportion of patients eligible
for hepatic resection. Along with the advancements in the amalgamation of perioperative
and surgical management, the use of effective chemotherapies, targeted biological therapies
and novel methods of delivering these targeted therapies locally (e.g., hepatic intra-arterial
chemotherapy, RFA, stereotactic radiotherapy) [9], as we strive to decrease perioperative
morbidity and mortality, increase long-term survival by increasing the number of patients
who are able to undergo complete hepatic resections (Figure 1).
Chemotherapy is a chemically constituted anticancer therapy that acts by reducing
the tumour burden and facilitates the destruction of rapidly growing cancer cells in the
body. In colorectal cancer, the most used are shown in Table 1.
Table 1. Combined Chemotherapy Regimens.
Names of Combined Chemotherapy
Regimens Components of Combined Chemotherapy
FOLFOX Folinic Acid, Fluorouracil and Oxaliplatin.
FOLFORI 5-Fluorouracil and High-Dose Leucovorin
FOLFIRI Folinic Acid, Fluorouracil and Irinotecan
FOLFOXIRI Folinic Acid, Fluorouracil and Oxaliplatin.
CAPOX or XELOX Oxaliplatin and Capecitabine
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Figure 1. Pathway of managing resectable and unresectable colorectal liver metastases. Figure 1. Pathway of managing resectable and unresectable colorectal liver metastases.
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With regards to targeted therapies used in the treatment of colorectal cancer and their
metastases, the main forms of this type of therapy are Tyrosine Kinase Inhibitors, BRAF
(proto-oncogene B-Raf or v-Raf murine sarcoma viral oncogene homolog B) inhibitors and
epidermal growth factor receptor (EGFR) inhibitors (Figure 2).
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Figure 2. Molecular Targets for m RC in the liver. c-MET: tyrosine-protei kinas Met recep-
tor, HER 2: Human Epidermal Growth Factor Receptor-2, EGFR: Epidermal growth factor recep-
tor, VEGFR: Vascular Endothelial Growth Factor Receptor PI3K: Phosphoinositide 3-kinase, RAS-
RAF-MEK-ERK pathways also known MAPK/ERK pathway corresponds to the Ras/Raf/Mitogen-
activated protein kinase/ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK) cascade
couples signals from cell surface receptors to transcription factors, regulating gene expression and
mCRC: metastatic colorectal cancer.
Tyrosine Kinase Inhibitors, also known as kinase inhibitors, located on cellular surfaces
and intracellularly, are proteins involved in cell to cell signalling and are key elements in
cell function. Kinase inhibitors like Regorafenib block several kinase proteins that assist
the tumour cell growth and tumour blood vessel development, similar to anti-angiogenic
inhibitors (Table 2). Blocking these proteins can impair tumour growth and function. BRAF
gene and its proteins play a fundamental role in colorectal cancer (CRC). Some CRC cells
produce abnormal BRAF proteins that promote tumour growth, hence being an important
therapeutic target. A limiting factor in using BRAF inhibitors is that BRAF inhibitors
are unlikely to work on patients with colorectal cancers that have normal BRAF genes.
Epidermal growth factor receptor (EGFR) is a protein-based receptor that also assists cancer
cell growth. Primarily, EGFR inhibitors are used in patients with advanced colon or rectal
cancers.
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Table 2. Types of anticancer therapies.
Types of Therapy Definition Examples of Type of Therapy
“Classical” Cytotoxic
Chemotherapies
Therapies that can be delivered
intravenously or orally. It can be given
during the neoadjuvant, adjuvant or
palliative setting and can be given either
systemically or regionally.
FOLFOX (also known as Oxaliplatin de Gramont
or OxMdG, which means modified Oxaliplatin
de Gramont) (Folinic acid, fluorouracil and
oxaliplatin)
FOLFORI (5-Fluorouracil and High-Dose
Leucovorin)
FOLFIRI (Folinic acid, fluorouracil and
irinotecan)
FOLFOXIRI (folinic acid, 5-fluorouracil,
oxaliplatin and irinotecan)
CAPOX (capecitabine plus oxaliplatin) or
XELOX (xeloda® = capecitabine plus
oxaliplatine)
Targeted Therapies
Therapies that target specific molecules,
including receptors, proteins, genes
which impair the development and
propagation of tumour growth.







Therapies against which targets the
protein (VEGF) that promotes vessel
development and growth in order to
facilitate transportation of nutrients to the





Therapies that utilize and facilitate a
patient’s own immune system in







Biotherapies are a form of therapies encompassed under the umbrella term of im-
munotherapies in which these agents utilize and enhance a patient’s own immune system
to treat cancer.
3. Current Management of Liver Metastases from Colorectal Cancers
3.1. Initial Assessment
Patients with suspected CRC will have undergone several pre-operative evaluations,
including have CT Thorax, Abdomen and Pelvis with Contrast. Occasionally, these prelim-
inary imaging modalities identify the presence of a potential primary CRC and/or lesions
that are detected within the liver (metachronous or synchronous) [10,11]. We then opt
for additional imaging in the format of a contrast magnetic resonance imaging (MRI) of
the Pelvis (in case of rectal cancers) and an MRI of the Liver with contrast. MDT involv-
ing colorectal surgeons, HPB surgeons, radiologists and oncologists decide on the most
favourable management plan given the patient’s pathology encompassing CRC resection,
chemotherapy with or without biological agents and hepatic resection. Resectable hepatic
disease is considered for pre-operative chemotherapy followed by resection or attempt for
immediate curative resection (R0) if pathology meets resectability criteria [12]: (i) CRLM
must be resectable with negative margins and allow for the preservation of at least two
contiguous liver segments with intact inflow, venous outflow and biliary drainage; (ii) the
volume of this future liver remnant (FLR) depends on the functionality (~30% of total liver
volume for a normal liver, FLR > 30%, if liver fibrosis is present). The tumour number and
location and position are determined with imaging pre-operatively and intra-operatively
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as previously discussed, and for deeper-seated lesions in the liver parenchyma and smaller
than 2 cm in diameter, combined radiofrequency ablation (RFA) is frequently used to
minimize liver tissue loss and limits post-resection hepatic dysfunction.
Hepatic resection is considered the primary operation for mCRC if patients have
a high tumour burden or with primary tumours located in the rectum, which will re-
quire pre-operative chemo-radiotherapy [13,14]. Major hepatic resection is defined as the
resection of 3 or more hepatic segments associated with an increased mortality rate of
~15%. The use of neoadjuvant chemotherapy in combination with targeted biotherapies
has shown to increase resectability in complex CRLM and unresectable CRLM prior to
hepatic resection. In spite of the neoadjuvant therapies, there a credible risk associated
with chemotherapy-associated liver injury (CALI), which can impact patient suitability
for hepatic resection [15,16]. Hepatic changes such as sinusoidal obstruction, peri-portal
inflammation, and steatohepatitis are associated with neoadjuvant therapies, which can
alter a patient’s overall outcome [17]. Specifically, the direct use of oxaliplatin is linked
to the development of sinusoidal obstruction syndrome in up to 38% of patients, while
steatosis and steatohepatitis complicated 9.3% of patients receiving irinotecan. Patients
with the following complications were more likely to suffer post-operative complications
(severe sinusoidal dilation (OR 1.73) or steatohepatitis (OR 2.08)) [12].
3.2. Perioperative Chemotherapy
The use of chemotherapy in patients with CRLM is usually reserved for patients with
borderline resectable disease and patients with unresectable disease (Figure 1). Chemother-
apy aids in improving overall patient survival outcomes by facilitating hepatic resections.
Recommended guidelines suggest that using FOLFOX or CAPOX, essentially oxaliplatin-
based chemotherapy during the neoadjuvant period, is the ideal choice for patients
with borderline resectable CRLMs, while FOLFIRI or FOLFOXIRI are alternative options
(Table 1) [18]. During the period of delivery of chemotherapy, rigorous interval imaging
is required to elicit the timepoint at which the CRLM become clearly resectable from bor-
derline resectable and prepare for hepatic resection [19]. Monitoring CRLM during the
active treatment with chemotherapy with or without other targeted therapies is extremely
important as there is a genuine risk of in this group of patients developing “disappearing
CRLM”, which can complicate the treatment pathway of affected patients [20].
For unresectable disease, conversional chemotherapy with and without biological
therapies is used to convert unresectable disease into resectable disease [21,22]. In stan-
dard systemic chemotherapy regimens with oxaliplatin +/− irinotecan-based regimens
in combination with 5-FU (FOLFOX, FOLFIRI and FOLFOXIRI), studies have shown that
chemotherapy has been able to facilitate resections in ~40% of initially unresectable pa-
tients [23–25]. Neoadjuvant chemotherapy in unresectable disease has demonstrated a
reduction in the size of the liver metastases by ~50% in tumour mass: this was seen in
upwards of 60% of patients with unresectable CLM with complete resection in 40% of these
patients [19,26,27].
A recent systematic review and meta-analysis reviewed the effectiveness of using
neoadjuvant chemotherapy plus molecular targeted therapy in unresectable CRLM [28].
The study identified that using chemotherapy plus targeted biological therapy for un-
resectable CRLM patients had an impact on the overall response rate (ORR). ORR is a
measure of the proportion of patients whose disease reduced (partial response–PR) and/or
disappears (complete response–CR) after treatment [29]. The study highlighted that pa-
tients who received chemotherapy plus molecular targeted therapy had a higher overall
response rate when compared with patients using chemotherapy alone (68% vs. 43%), but
evidence to suggest improved overall survival (OS) remains inconclusive [28,30].
The EPOC trial also evaluated the Progression-Free Survival (PFS) in patients with
unresectable CRLM, which is an important measure in treated metastatic disease. PFS
is used as a primary endpoint in trials evaluating the treatment of metastatic cancer.
PFS is the length of time during and after the treatment (chemotherapy +/− targeted
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biological therapies) of unresectable CRLM that a patient lives with stable or improved
metastatic disease. PFS for unresectable CRLM patients undertaking perioperative systemic
chemotherapy plus EGFR-inhibitor (Cetuximab) vs. chemotherapy indicated that this
cohort of patients, who received specifically chemotherapy plus cetuximab, essentially
experienced worse PFS when compared with the chemotherapy control group (14.1 vs.
20.5 months in control) [12,22]. The trial concluded that cetuximab should not be given
with perioperative chemotherapy regimens; however, the trial emphasized the use of
other groups of targeted biological therapies that showed improved PFS and OS. Further
combinations of systemic chemotherapeutics and targeted biotherapies were reviewed;
Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, was combined with
FOLFIRI (Folinic acid, fluorouracil and irinotecan) as joint neoadjuvant therapy and yielded
a response rate of 66.7% in resectable CRLMs; however, the survival outcomes and benefits
are still to be determined.
The PERIMAX trial evaluated the benefits and limitations of a highly active chemother-
apy +/− targeted biological therapy regimens in the perioperative and post-operative
setting for resectable and unresectable CRC. Patients with resectable liver metastases were
randomized into perioperative treatment with FOLFOXIRI and bevacizumab or post-
operative FOLFOX, and patients with unresectable mCRC being randomized between
FOLFOX and bevacizumab with or without irinotecan. Analysis suggests that the use of
cetuximab plus chemotherapy had no impact on overall survival compared with chemother-
apy alone for the unresectable CRLM group patients and in resectable CRLM patient cohort,
cetuximab use adversely affected OS (HR = 0.95 and 2.35, respectively) [22]. Perioperative
chemotherapy offers an opportunity to reduce cancer recurrence post-resection in approxi-
mately 70% of patients after resection and drives complete eradication of CRC, and thereby
imparting a survival benefit [31,32].
3.3. Synchronous Disease
The liver along with the lung are the most common sites of the metastases of colorectal
cancer. Studies have shown about 40–50% of CRC patients will develop liver metastases
at a point during the course of CRC disease [33,34]. About 20% of patients often have
established synchronous liver metastases when the diagnosis of primary colorectal cancer
is made. Synchronous liver metastases are associated with poor outcomes likely caused
by poor tumour biology and complex treatment plans [13,35]. Hepatic resection is a
definitive treatment option to achieve long-term survival and overall survival, as studies
have shown that after primary and secondary resections. CRLM resection offered an
overall median survival of 3.6 years; 5- and 10-year survival ranged from 16% to 74%
(median 38%) and 9% to 69% (median 26%), respectively. Hepatic resections are divided
into selective staged resection, delayed resection or simultaneous resections, with a higher
proportion of teams opting for selective staged resection of CRCs, as this is associated
with fewer risks accompanied with operating at two sites in simultaneous resection [36,37].
Risks associated with simultaneous resection include intraperitoneal infection, anastomotic
fistula and hepatic insufficiency, as well as associated higher mortality. Hepatic resections
are divided into three groups: (1) sequential resection (SeR), in which surgical teams are able
to resect colorectal cancer and liver metastases without delivering interval chemotherapy;
(2) delayed resection (DeR) in which we deliver interval chemotherapy between staged
colonic cancer resection and hepatic resection of CRC metastases; and (3) simultaneous
resection (SiR), single-stage resection of primary colorectal cancer and liver metastases
simultaneously. SiR is performed in patients who fulfil certain criteria (1) the primary
tumour was located in the right colon regardless of the tumour disease burden of liver
metastases; (2) the tumour disease burden was not heavy, and the tumour number was less
than two if the primary tumour was located in the left colon or rectum [38,39].
A staged resection is an important option in managing patients with high tumour
burden (tumour number greater than three), rectal tumours requiring chemo-radiotherapy,
and patients with significant co-morbidities who all are unlikely to tolerate simultaneous re-
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sections [40,41]. DeR selects patients post-primary surgery with resectable liver metastases
who were treated with chemotherapy prior to the second resection operation and patients
with unresectable liver metastases who were treated with chemotherapy +/− targeted
biological therapies and then further evaluated and discussed in MDT after interval [12,42].
3.4. The Issue of Disappearing Liver Metastases
Pre-operative chemotherapy in patients with resectable CRLM can drive the phe-
nomenon of “disappearing” CRLM (DLM) in a quarter of resectable CRLM lesions [20].
This phenomenon is identified using imaging. Despite the positive radiological response,
80% of these lesions remain viable metastases [43]. The risk of DLM is a valid concern
when commencing resectable patients on chemotherapeutic agents. CRLMs, particularly
in resectable patients, ideally will need to be identified on pre-operative contrast-enhanced
imaging, and initially, resection or ablative therapies should be considered as initial treat-
ment. However, the majority of these DLMs are still apparent and identifiable intraopera-
tively under direct vision and use of intraoperative ultrasonography (IOUS) imaging [44,45].
In patients with high-risk lesions (e.g., deep parenchymal lesions and smaller lesions),
often, MDTs opt to limit the cycles of chemotherapeutics and proceed to surgery first. In
the event where we are unable to excise all the DLMs or other sites of metastatic disease,
these patients often rigorously followed up and managed upon macroscopic recurrence
with a staged resection approach [46].
3.5. Patients with Initially Resectable Disease
The use of chemotherapy in patients with initially resectable disease varies from
one centre to another; there is still no strict guidelines in the approach to integrating
hepatic mCRC resection with systemic chemotherapeutics [47,48]. If patients have four
or fewer mCRC resectable lesions with a primary colorectal tumour, then often centres
opt for resection first over chemotherapy, unless there is a predicted strong response
against chemotherapy. Initial chemotherapeutic treatment is reserved for patients with
good exercise tolerance, few co-morbidities, multi-lobar tumour involvement and regional
lymph node involvement. These patients are then re-evaluated with interval imaging
6–8 weeks to assess response to the chemotherapy and then re-discussed in MDT prior to
surgical resection.
Beppu et al. demonstrated in the EPOC trial highlighted that the optimal neoadjuvant
combination regime for patients with initially resectable CRLM with RAS mutations as
such FOLFOX, FOLFIRI and/or CAPOX with or without bevacizumab; FOLFIRI with
or without cetuximab or panitumumab; or FOLFOX with or without panitumumab or
cetuximab (if RAS wild type) [49]. The consideration of using targeted biological agents in
tumours that lack RAS/BRAF mutations in left-sided CRC. Research has shown that the site
of the primary tumour influences the effectiveness of anti-epidermal growth factor receptor
(EGFR) agents; we avoid the use of an anti-EGFR agent in right-sided primary tumours,
even if RAS/BRAF wild type [25,50]. Evidence from the EPOC trial highlights that in
272 patients with resectable hepatic metastases of KRAS wild-type mCRC were given
FOLFOX with or without cetuximab, pre-operatively and post-operatively for 12 weeks,
and it is clear that the addition of cetuximab was associated with significantly worse
progression-free survival (PFS) (15.5 versus 22.2 months) [22,51,52].
3.6. Patients with Initially Unresectable Metastases
There is a necessity to utilize chemotherapy and targeted biological therapies in
patients with unresectable disease in order to downstage their condition. With combination
conversional therapy, there is a 10–15% likelihood of converting unresectable CRLM into
resectable CRLM. Patients with unresectable CRLM often undergo prolonged periods
of chemotherapeutic and biological therapies. Prolonged exposure to such therapies
can trigger perioperative and post-operative complications, including liver toxicity and
hepatic dysfunction [53–55]. The EPOC trial reported ~12–33% of patients with initial
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unresectable CRLM who were converted to resectable to allow surgical intervention to
achieve a complete resection (R0) [22].
With the combined chemotherapeutics and targeted biotherapies, the 5-year survival
rates average 30% to 35%, which is significantly better when patients just used chemother-
apy alone; the 5-year survival rates on average were 10% to 11% [56]. The benefit from the
addition of a biologic agent is controversial but, in the CRYSTAL [57,58], DEEPER [59], and
OPUS [51,60] trials both have shown modestly improved resectability rates when using
chemotherapeutics plus targeted biological agents vs. chemotherapy alone (3.7% (chemo.
alone) vs. 7% (chemo. plus, targeted biological agents) and from 2.4% (chemo. alone)
vs. 4.7% (chemo. plus targeted biological agents) respectively [57,58]. This, as a result,
increases the number of patients potentially eligible for resection and improve outcomes.
With mCRC/CRLM with KRAS mutations and KRAS wild-type in the OPUS trial, the
use of FOLFOX plus cetuximab increased resectability compared with just chemotherapy
alone (4% vs. 10%) [61,62]. EPOC trial data recommended complete avoidance of a combi-
nation of an anti-EGFR agent plus oxaliplatin, even in patients with left-sided tumours.
The benefit of anti-EGFR agent plus oxaliplatin is marginal at best, and the complications
associated with prolonged therapeutics exposure outweighs its marginal and unestablished
benefits [63].
3.7. Adjuvant Treatment When Resectable
Similar to neoadjuvant therapy in resectable patients, there are no clear guidelines or
best post-operative strategy. However, common practice is that after confirmed complete
resection, most centres deliver a total of a six-month course of systemic chemotherapy,
including chemotherapeutics delivered as neoadjuvant therapy. The frontrunners of agents
used are FOLFOX alone, or CAPOX can be used. With regards to the use of chemothera-
peutics and targeted biological agents in the adjuvant setting after resection of CRLM, the
addition of bevacizumab with conventional chemotherapy did not prolong survival but
induced biliary toxicity [64–66].
4. Biotherapies and Their Action Modes
Biological therapies are credited with increasing median overall survival in colorectal
cancer, and it is a vastly active area of cancer research with the sole objective of improving
patient outcomes in conjunction with co-existing therapies. Biotherapies are a form of
targeted therapeutics with a biological focus on a colorectal cancer cell, key for cancer
cell function including cell surface markers and receptors, assisting in the host’s immune
response by (1) inducing the immune system to target cancer cells and (2) targets the
cancer cells, controlling the on or off cell signals that assist the CRC cells in eluding the
immune system cells (e.g., immune checkpoint inhibitors which target specific chemical
receptors on cancer cells, blocking the signals the cancer cells send to suppress the immune
system [67–69]. There are a number of types of biological therapies that extend to: adoptive
cell transfer, immunomodulators, chimeric antigen (CAR) T cell therapy, monoclonal
antibodies, cancer vaccines and immune checkpoint inhibitors.
4.1. Immunotherapy and Adoptive Cell Transfer
Immunotherapy has become the frontrunner treatment option for the management of
several malignancies that have become unresponsive and insensitive to chemo-radiotherapy
and thereby prevents principal pathways of treatment failure, which ultimately leads to
metastasis. The mainstay treatment option for CRC showed minimal improvement in
the 5-year survival rate and prevented re-occurrence after apparent complete resection
even with relapses that followed a complete surgical hepatic resection. The function of
immunotherapies acts on blocking tumourigenic interactions within the cancer-stromal
microenvironment and inhibiting the action of secreted cytokines and cell surface receptors
these cytokines bind to, which are involved in tumorigenesis [70,71].
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Immunotherapies facilitated the blocking of cytokine signalling to target receptor,
CCR5, which prevents the progression of the tumour microenvironment via the inhibition
of the interactions myeloid cells (MDSCs) and T cells and therefore achieved clinical
benefits among patients with advanced/mCRC [72]. The liver’s microenvironment is
immunosuppressive in nature and aids the development of metastatic regions within
the hepatic microenvironment. The presence of MDSCs has proven a key mediator for
metastases. The effectiveness of CAR-T cells engineered against hepatic metastases can be
weakened by the presence of MDSCs [73].
Hepatic MDSCs express PD-L1 (Programmed death-ligand 1) which binds onto the PD-
1 on the T cell surface promotes cell death, and prevents the activation and differentiation
of T cells and, therefore, unable to action its anti-tumour function [74,75]. By reducing
MDSC accumulation within the liver via PD-L1 blockade from immunotherapy like CAR-T
cell therapy, you are then able to promote and achieve antitumor responses. Moreover, the
blockade of molecules involved in MDSC biology and function augmented the efficiency
of adoptive cell therapy against CRC metastases. Adoptive cell therapy (ACT) using
tumour-infiltrating lymphocyte (TILs) has shown significant efficacy in patients with
metastatic melanoma and might be a feasible option for most CRC patients with liver
metastases [76,77].
4.2. Targeted Biological Therapy
Targeted therapies can work on cancerous cells by directly inhibiting cell proliferation,
differentiation, and migration [78]. Targeted biological therapies have been a long-standing
concept initially thought to expand on current cancer treatment regimes. The targets are
the functional components of tissues and tumours, including blood vessels and immune
cells [79]. Targeted biological therapy for mCRC has become an important aspect of the
“conversional” management of unresectable CRLM. Over time, research has allowed us to
understand tumour biology and to understand the mechanism of their targets. The two
main mechanisms included the angiogenesis pathway (inhibited by bevacizumab) and
epidermal growth factor receptors (EGFRs: cetuximab and panitumumab) [80]. EPOC trial
provides evidence that adding targeted biological therapeutics with chemotherapeutics
causes an increase in the number of candidates eligible for surgery. In general, response
rates appear to be highest with the EGFRIs; therefore, these agents may potentially also
lead to greater resection rates.
The tumour microenvironment, including local blood vessels and immune cells, might
also be altered by targeted drugs to impede tumour growth and enact stronger immune
surveillance and attack. For targets outside cells, such as cell surface receptors or membrane-
bound sites, monoclonal antibodies or therapeutic antibodies can recognize and bind them
to directly regulate downstream cell cycle progression and cell death [81]. In addition,
certain monoclonal antibodies work on cells other than cancer cells, such as immune cells,
which helps to manipulate the immune system to attack human cancer.
As mentioned earlier, intrinsic or acquired resistance may exist and identifying these
potential resistances to targeted therapies are of high importance: (1) Predicting resistance
to the Epidermal Growth Factor Receptor (EGFR)-targeted monoclonal antibodies: different
studies have demonstrated that combined detection of NRAS, PTEN and PI3K (especially
exon 20) genes status in wild-type KRAS CRC patients, can identify patients who are
more prone to not respond to anti-EGFR therapies [82] and (2) identifying intrinsic and
acquired resistance to drugs targeting the EGFR-RAS-RAF pathway in CRC, in addition
to identifying potential biomarkers for resistance of tumours that are dependent on MEK
signalling: the PI3K/mTOR pathway may be involved in the resistance to MEK inhibition
in CRC but also in the RAS-RAF-MEK-MAPK pathway [83].
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4.3. Future of Biotherapies for Liver Metastasis in Colorectal Cancer
4.3.1. Immunotherapy
Colorectal liver metastases remain associated with poor overall prognosis, even with
surgical resection of the tumour at its primary site [84]. As with other cancers, immunosup-
pressive micro-environments within the liver support tumourigenesis to develop hepatic
metastases [85]. For instance, myeloid-derived stem cells (MDSC’s) residing within the
liver micro-environment can express PD-L1, which inhibit the activation and proliferation
of T cells by interacting with PD-1 on T cells. Owing to the complex interaction between
the immune system and tumour cells, immunotherapy has achieved a certain [86] degree
of success in the treatment of advanced solid tumours in recent years [87]. Principally,
immunotherapy aims to enhance or amplify the anti-tumour response by the patient’s
own immune system by augmenting the innate immunity and anti-tumour function of T
cells and by targeting immunosuppressive tumour-associated macrophages [88]. Broadly,
immunotherapies include: (i) immune checkpoint inhibitors (ICIs); (ii) cancer vaccines; and
(iii) other biotherapeutics such as chimeric antigen receptor (CAR) T cells. These therapies
are effective in treating a variety of cancers [86], including mCRC, especially mCRC with
deficient DNA mismatch repair (dMMR) genes [89].
4.3.2. Immunotherapy in Colorectal Liver Metastasis
Several immunotherapy agents have been being evaluated in prospective randomized
clinical trials (RCT) in CLM [90]. Firstly, RCT’s on pembrolizumab demonstrated improve-
ment in progression-free survival rates compared to no treatment in MSI-H CRC’s (11%
vs. 0%) [91]. Compared to MSI cancers, MSS cancers are less sensitive to immunotherapy
alone. This is because dMMR CRCs are prone to be heavily infiltrated by CD8+ T cells and
highly expressed immune checkpoint molecules, including PD-L1 [92]. In dMMR CRC and
pMMR CRC, the disease control rate at 12 weeks was 90% and 11%, respectively [93]. This
might partly explain why anti-PD-1/PD-L1 therapies are correlated to antitumor responses
in MSI-H or dMMR mCRC. Therefore, novel combination approaches are being investi-
gated to enhance therapeutic efficiency in patients who might be sensitive to combination
treatments [94]. Secondly, the use of nivolumab in conjunction with or without ipilimumab
in dMMR or MSI-H mCRC have been assessed in the phase II CheckMate 142 RCT. Prelim-
inary data revealed an objective response rate (ORR) and disease control rate of 31% and
69%, respectively. When ipilimumab was added to nivolumab, the ORR and disease control
rates of 41% and 78%, respectively, were noted [95]. Nivolumab has been approved for
patients harbouring dMMR/MSI-H mCRC who experience disease progression following
treatment of fluoropyrimidine, oxaliplatin, and irinotecan [96]. However, response rates
varied in CRC with distinct genomic alterations [97].
Thirdly, adoptive cell therapy (ACT) has shown improvement in survival in patients
with metastatic melanoma. Similar responses have been observed in individual patients
with CRC after ACT [98,99]. CAR therapy aims to improve NK cell tumour response.
A recent study confirmed that CAR-NK cells could recognize tumour cells and exhibit
anti-tumour effects in metastatic CLM patients [100]. This is an achievable way to combat
liver metastasis by using new techniques developed in recent years. Because it can be
harvested aseptically and does not contaminate the intestinal flora, liver metastasis may
be an ideal source of tumour-infiltrative lymphocytes for the treatment of ACT in CRC
patients [97].
5. Beyond the Treatment of CRC and Its Progression: Prevention of CRC Occurrence
and Metastatic Recurrence Is of High Importance
The key to primary prevention of CRC occurrence is how successful our methods of
educating the population on highlighting high-risk factors, dietary advice and promoting
healthy lifestyles. These include identifying patients that are genetically at risk or are in
high-risk families (Families with Familial Adenomatous Polyposis [FAP], Hereditary Non-
Polyposis Colorectal Cancer [HNPCC or Lynch syndrome]) and identifying family history
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for the presence of previous CRC or polyps [101]. Genetic mutations play an integral
role in CRC. Recent studies have highlighted important germline mutations at different
locations of a number of target genes [102]. Patients with CRC will often harbour potentially
pathogenic germline mutations. Patients can have germline mutations in non-mismatch
repair genes, including MUTHY, RAD50, TP53, and a rarer cohort of other genes [103].
Both young adults or those who have been diagnosed with early-onset CRC and mCRC
often have comparable mutations in TP53, APC, KRAS, SMAD4, BRAF, FAF1 and BRCA2
genes but varied tumour mutation burden (TMB), with a higher TMB linked to early-onset
CRC [104]. On a cellular pathway level, genetic mutations in cellular pathways WNT and
TGF-B pathways are also associated with unfavorable OS in CRC. Therefore, screening and
early detection is important in improving OS [105].
Early detection and screening have played an important role also in the CRC occur-
rence prevention of disease’s progression; by means of patient acknowledgement and
awareness of symptoms, it aids in the reduction of time from diagnosis to commencement
of treatment [106]. National early detection initiatives have also reduced the stigma asso-
ciated with the perception of CRC and thereby have increased population engagement
and CRC detection [107]. In regards to prevention of CRC metastatic recurrence, routine
surveillance following national guidelines, but also neoadjuvant and adjuvant therapeu-
tics to downstage disease and reduce metastatic disease, all these elements assist in the
survivorship in affected patients [108].
5.1. Environment, Diet, Lifestyle, Microbiome, and Immune System Together Influence Pathogenic
Mechanisms of Colorectal Carcinogenesis
5.1.1. Dietary Advice
Diet has a proven link with the risk of developing CRC. Dietary elements such as
foods with high dietary fats, red meats, high consumption of alcohol are all associated
with increasing the risk of promoting CRC [109]. In contrast, the consumption of fruits,
vegetables, high fibre foods, foods rich in vitamin B6 and D are associated with lowering
the risk of CRC development. A recent systematic review by Siegel et al. [110] supports
that the integration of healthy eating and physical activity substantially lowers the risks of
developing CRC.
5.1.2. Pre-Existing Conditions
Conditions including inflammatory bowel disease (IBD), primarily Ulcerative colitis
(UC) more than Crohn’s disease (CD), hypertension, chronic kidney disease, hyperlipi-
daemia and obesity and others are linked to increased risk of the development of CRC.
There is a clear association between ulcerative colitis, the chronicity of the disease and
colonic neoplasia [111]. The presence of pancolitis in UC increases the risk of CRC by
up to 15 times when compared to the average national risk. UC patients also undergo
rigorous screening for polyps. CD sufferers who have extensive and prolonged occurrences
of pancolitis have a relative risk to chronic pancolitis similar to that of UC patients [112].
Young adult and paediatric patients who have been diagnosed with malignancy and treated
with abdominopelvic radiation has a direct correlation to and increases the relative risk of
developing CRC. Co-morbidities, including diabetes mellitus (DM), obesity, hypertension
and chronic kidney disease, is associated with an elevated relative risk of CRC [113].
5.1.3. Gut Microbiome Immunology and CRC
The intestinal microbiota is composed of a large, varied array of micro-organisms. It is
estimated that the human intestinal microbiota is composed of 1013 to 1014 microbes [114].
These microbes play an essential role in establishing ‘gut homebiosis’ and preventing
gut dysbiosis, which drives disease and pathology. Recent articles have identified that
micro-organisms such as Streptococcus Bovis, enterotoxigenic Bacteroides fragilis, Fusobacterium
nucleatum, Enterococcus faecalis, Escherichia coli, and Peptostreptococcus anaerobius as CRC
candidate pathogens [115]. The composition and balance in the type of micro-organisms is
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the key to reducing the risk of developing a range of conditions and diseases. Alterations
in the composition of the gut microbiota shape and alter the intestinal epithelium and its
metabolic activity. Streptococcus Bovis, which is normally found in the gastrointestinal tract,
can act as an early indicator for CRC [116] if increasing concentrations of this microbe are
detected. Microbes such as enterotoxigenic Bacteroides fragilis, Fusobacterium nucleatum,
Enterococcus faecalis, Escherichia coli, and Peptostreptococcus anaerobius are found in increased
quantities when compared to healthy individuals’ intestinal microbiota [117]. Even in
the presence of colorectal adenomas, we see a considerable change in the concentration
of the aforementioned microbes in the gut microbiota. There is a capability of being
able to quantify and detect the microbiota alterations as alternative biomarkers for CRC
detection [118].
5.2. Molecular Pathology Research towards the Environment, Lifestyle, Microbiome, Immunity for
Prevention, Treatment and Clinical Outcomes Regarding CRC Management
The mechanisms in which these microbiota drive the pathogenesis of CRC are linked
to an inflammation theory. This corresponds to the secretion of toxins by certain microbes,
which in turn damages intestinal epithelium and epithelial cell DNA, thus initiating the
CRC process [119]. With the presence of dysbiosis due to the increase in specific gut mi-
crobiota, there is an increase in causative microbes, which triggers chronic inflammation
and consequently tumorigenesis [120]. There is a loss of the intestinal mucosal barrier,
an important factor in dysbiosis and inflammation propagation. The loss of the mucosal
layer results in the intestinal layer becoming highly permeable to the gut microbiota, which
initiates worsening inflammation and colitis [121]. Toll-Like Receptors (TLRs) and Pattern
recognition receptors (PRRs) are activated by components of the microbes of the gut flora,
including LPS (liposaccharide) found in the cell walls of microbiota [122]. Downstream
signalling and activation occur and drive the production of inflammatory cytokines such
as IL-17, IL22 and Il-23; this then eventually promotes tumour cell proliferation by ac-
tivation nuclear factor-κB (NFκB) and STAT3 signalling pathway and eventually CRC
development [123].
6. Conclusions
In summary, treatment of mCRC, especially CLM, is challenging because of its im-
munosuppressive microenvironment. Therefore, immunotherapy may be a novel thera-
peutic strategy for this cohort of patients. Despite increasing clinical data regarding the
therapeutic role of immunotherapy among dMMR or MSI-H mCRC, evidence for most
patients harbouring pMMR or MSS tumours still do not benefit from immunotherapeutic
agents [124]. This may be explained by the collective inhibitory impact of multiple net-
works on effector immune cells to enable CRC to develop and form metastases within
the tumour micro-environment [125]. This necessitates further research to develop novel
therapeutic approaches or identify biomarkers for personalized modulation of the tumour
micro-environment to reverse immunosuppression, thus improving clinical outcomes [126].
Specifically, the immune cells in the tumour micro-environment, together with the sol-
uble factors, might also be potential targets to treat CLM. Outside of the discovery of
new immunotherapy targets, further directions should be focused on relieving CLM from
the inhibitory networks and activation hurdles constituting the TME by combining im-
munotherapies with other therapies.
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